Chantal Guillemette

List of Publications by Year
in descending order

182	8,843	47409	56606
papers	citations	49 h-index	87 g-index

185	185	185	8680
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Follicle-stimulating hormone (FSH) levels prior to prostatectomy are not related to long-term oncologic or cardiovascular outcomes for men with prostate cancer. Asian Journal of Andrology, 2022, 24, 21.	0.8	2
2	Variability in testosterone measurement between radioimmunoassay (RIA), chemiluminescence assay (CLIA) and liquid chromatography-tandem mass spectrometry (MS) among prostate cancer patients on androgen deprivation therapy (ADT). Urologic Oncology: Seminars and Original Investigations, 2022, , .	0.8	0
3	Sex steroid modulation of macrophages within the prostate tumor microenvironment.. American Journal of Clinical and Experimental Urology, 2022, 10, 98-110.	0.4	0
4	A liquid chromatography-mass spectrometry assay for the quantification of nucleotide sugars in human plasma and urine specimens and its clinical application. Journal of Chromatography A, 2022, 1677, 463296.	1.8	3
5	Rationale for the combination of venetoclax and ibrutinib in T-prolymphocytic leukemia. Haematologica, 2021, 106, 2251-2256.	1.7	7
6	Urinary oestrogen steroidome as an indicator of the risk of localised prostate cancer progression. British Journal of Cancer, 2021, 125, 78-84.	2.9	5
7	IL15RA and SMAD3 Genetic Variants Predict Overall Survival in Metastatic Colorectal Cancer Patients Treated with FOLFIRI Therapy: A New Paradigm. Cancers, 2021, 13, 1705.	1.7	10
8	KLF5 and NFYA factors as novel regulators of prostate cancer cell metabolism. Endocrine-Related Cancer, 2021, 28, 257-271.	1.6	15
9	Circulating Levels of Sex Steroid Hormones and Gastric Cancer. Archives of Medical Research, 2021, 52, 660-664.	1.5	8
10	A quantitative analysis of total and free 11-oxygenated androgens and its application to human serum and plasma specimens using liquid-chromatography tandem mass spectrometry. Journal of Chromatography A, 2021, 1650, 462228.	1.8	15
11	Associations Between Prediagnostic Concentrations of Circulating Sex Steroid Hormones and Liver Cancer Among Postmenopausal Women. Hepatology, 2020, 72, 535-547.	3.6	23
12	Reply to Comment on â€œUGT2B17 modifies drug response in chronic lymphocytic leukaemiaâ€• British Journal of Cancer, 2020, 123, 1347-1348.	2.9	0
13	DNA repair gene polymorphisms, tumor control, and treatment toxicity in prostate cancer patients treated with permanent implant prostate brachytherapy. Prostate, 2020, 80, 632-639.	1.2	3
14	UGT2B17 modifies drug response in chronic lymphocytic leukaemia. British Journal of Cancer, 2020, 123, 240-251.	2.9	13
15	Glucuronidation of Abiraterone and Its Pharmacologically Active Metabolites by UGT1A4, Influence of Polymorphic Variants and Their Potential as Inhibitors of Steroid Glucuronidation. Drug Metabolism and Disposition, 2020, 48, 75-84.	1.7	10
16	Endogenous estradiol and inflammation biomarkers: potential interacting mechanisms of obesity-related disease. Cancer Causes and Control, 2020, 31, 309-320.	0.8	16
17	Alternative promoters control UGT2B17-dependent androgen catabolism in prostate cancer and its influence on progression. British Journal of Cancer, 2020, 122, 1068-1076.	2.9	13
18	Emerging roles for UDP-glucuronosyltransferases in drug resistance and cancer progression. British Journal of Cancer, 2020, 122, 1277-1287.	2.9	89

#	Article	IF	Citations
19	Extragonadal Steroids Contribute Significantly to Androgen Receptor Activity and Development of Castration Resistance in Recurrent Prostate Cancer after Primary Therapy. Journal of Urology, 2020, 203, 940-948.	0.2	8
20	Contribution of extragonadal steroids to the androgen receptor activity and to the castration-resistance development in recurrent prostate cancers after primary therapy.. Journal of Clinical Oncology, 2020, 38, 148-148.	0.8	0
21	Associations Between Prediagnostic Concentrations of Circulating Sex Steroid Hormones and Esophageal/Gastric Cardia Adenocarcinoma Among Men. Journal of the National Cancer Institute, 2019, 111, 34-41.	3.0	42
22	Inactivation of Prostaglandin E2 as a Mechanism for UGT2B17-Mediated Adverse Effects in Chronic Lymphocytic Leukemia. Frontiers in Oncology, 2019, 9, 606.	1.3	12
23	PO-1088 DNA repair genes polymorphisms as biomarkers of tumor control in LDR BT prostate cancer patients. Radiotherapy and Oncology, 2019, 133, S604.	0.3	0
24	Combination of germline variations associated with survival of folinic acid, fluorouracil and irinotecan-treated metastatic colorectal cancer patients. Pharmacogenomics, 2019, 20, 1179-1187.	0.6	6
25	Germline variability and tumor expression level of ribosomal protein gene RPL28 are associated with survival of metastatic colorectal cancer patients. Scientific Reports, 2019, 9, 13008.	1.6	23
26	RPL28 Promoter polymorphism RS4806668 is associated with reduced survival in folfiri-treated metastatic colorectal cancer patients. Drug Metabolism and Pharmacokinetics, 2019, 34, S64-S65.	1.1	0
27	Factors Affecting Interindividual Variability of Hepatic UGT2B17 Protein Expression Examined Using a Novel Specific Monoclonal Antibody. Drug Metabolism and Disposition, 2019, 47, 444-452.	1.7	8
28	A Comprehensive Analysis of Steroid Hormones and Progression of Localized High-Risk Prostate Cancer. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 701-706.	1.1	13
29	188 DNA Repair Genes Polymorphisms, Tumour Control and Treatment Toxicity in Prostate Cancer Patients Treated with Permanent Implant Prostate Brachytherapy. Radiotherapy and Oncology, 2019, 139, S79.	0.3	0
30	Germline Polymorphisms in the Nuclear Receptors PXR and VDR as Novel Prognostic Markers in Metastatic Colorectal Cancer Patients Treated With FOLFIRI. Frontiers in Oncology, 2019, 9, 1312.	1.3	14
31	An LC-MS/MS method for quantification of abiraterone, its active metabolites D(4)-abiraterone (D4A) and 5Î±-abiraterone, and their inactive glucuronide derivatives. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2019, 1104, 249-255.	1.2	13
32	Combination of Venetoclax and Ibrutinib Increases bcl2-Dependent Apoptotic Priming, Reduces ITK-Phosphorylation and Is Clinically Promising in Relapsed/Refractory T-Prolymphocytic Leukemia. Blood, 2019, 134, 3965-3965.	0.6	1
33	Discordance between testosterone measurement methods in castrated prostate cancer patients. Endocrine Connections, 2019, 8, 132-140.	0.8	6
34	Post-transcriptional Regulation of UGT2B10 Hepatic Expression and Activity by Alternative Splicing. Drug Metabolism and Disposition, 2018, 46, 514-524.	1.7	6
35	Quantitative profiling of the UGT transcriptome in human drug-metabolizing tissues. Pharmacogenomics Journal, 2018, 18, 251-261.	0.9	28
36	Estradiol metabolites as biomarkers of endometrial cancer prognosis after surgery. Journal of Steroid Biochemistry and Molecular Biology, 2018, 178, 45-54.	1.2	15

#	Article	IF	Citations
37	PharmGKB summary. Pharmacogenetics and Genomics, 2018, 28, 127-137.	0.7	5
38	Sex-dependent association of circulating sex steroids and pituitary hormones with treatment-free survival in chronic lymphocytic leukemia patients. Annals of Hematology, 2018, 97, 1649-1661.	0.8	12
39	Association of STAT-3 rs1053004 and VDR rs11574077 With FOLFIRI-Related Gastrointestinal Toxicity in Metastatic Colorectal Cancer Patients. Frontiers in Pharmacology, 2018, 9, 367.	1.6	24
40	Identification of Metabolomic Biomarkers for Endometrial Cancer and Its Recurrence after Surgery in Postmenopausal Women. Frontiers in Endocrinology, 2018, 9, 87.	1.5	32
41	Serum Sex Steroids as Prognostic Biomarkers in Patients Receiving Androgen Deprivation Therapy for Recurrent Prostate Cancer: A Post Hoc Analysis of the PR.7 Trial. Clinical Cancer Research, 2018, 24, 5305-5312.	3.2	13
42	Association between circulating levels of sex steroid hormones and esophageal adenocarcinoma in the FINBAR Study. PLoS ONE, 2018, 13, e0190325.	1.1	38
43	Abstract 5237: Sex-dependent association of circulating sex steroids, pituitary hormones and treatment-free survival in patients with chronic lymphocytic leukemia. , 2018, , .		0
44	Abstract 2652: Metabolomics biomarkers for endometrial cancer and its recurrence after surgery in postmenopausal women. , 2018, , .		0
45	Abstract 3889: RPL28 promoter polymorphism rs4806668 is associated with reduced survival in FOLFIRI-treated metastatic colorectal cancer patients. Cancer Research, 2018, 78, 3889-3889.	0.4	1
46	Abstract A072: Serum sex steroids as prognostic biomarkers in patients receiving androgen-deprivation therapy for recurrent prostate cancer post-radiotherapy: A post hoc analysis of the PR.7 trial. , 2018, , .		0
47	Correlation between prostate volume and single nucleotide polymorphisms implicated in the steroid pathway. World Journal of Urology, 2017, 35, 293-298.	1.2	10
48	Cross-Talk between Alternatively Spliced UGT1A Isoforms and Colon Cancer Cell Metabolism. Molecular Pharmacology, 2017, 91, 167-177.	1.0	16
49	Sex steroid hormones in relation to Barrett's esophagus: an analysis of the <scp>FINBAR</scp> Study. Andrology, 2017, 5, 240-247.	1.9	9
50	Association Between Circulating Levels of Sex Steroid Hormones and Esophageal/Gastric Cardia Adenocarcinoma. Gastroenterology, 2017, 152, S34-S35.	0.6	1
51	Fluoxetine and its active metabolite norfluoxetine disrupt estrogen synthesis in a co-culture model of the feto-placental unit. Molecular and Cellular Endocrinology, 2017, 442, 32-39.	1.6	30
52	The R148.3 Gene Modulates Caenorhabditis elegans Lifespan and Fat Metabolism. G3: Genes, Genomes, Genetics, 2017, 7, 2739-2747.	0.8	5
53	Prediagnostic circulating inflammation markers and endometrial cancer risk in the prostate, lung, colorectal and ovarian cancer (PLCO) screening trial. International Journal of Cancer, 2017, 140, 600-610.	2.3	48
54	Testosterone suppression in the treatment of recurrent or metastatic prostate cancer â€" A Canadian consensus statement. Canadian Urological Association Journal, 2017, 12, 30-7.	0.3	16

#	Article	IF	Citations
55	Supplementary data: Testosterone suppression in the treatment of recurrent or metastatic prostate cancer â€“ A Canadian consensus statement. Canadian Urological Association Journal, 2017, 12, E45-6.	0.3	0
56	Endogenous Protein Interactome of Human UDP-Glucuronosyltransferases Exposed by Untargeted Proteomics. Frontiers in Pharmacology, 2017, 8, 23.	1.6	14
57	Improved Progression-Free Survival in Irinotecan-Treated Metastatic Colorectal Cancer Patients Carrying the HNF1A Coding Variant p.I27L. Frontiers in Pharmacology, 2017, 8, 712.	1.6	22
58	Divergent Expression and Metabolic Functions of Human Glucuronosyltransferases through Alternative Splicing. Cell Reports, 2016, 17, 114-124.	2.9	21
59	Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for UGT1A1 and Atazanavir Prescribing. Clinical Pharmacology and Therapeutics, 2016, 99, 363-369.	2.3	161
60	A Rare UGT2B7 Variant Creates a Novel N-Glycosylation Site at Codon 121 with Impaired Enzyme Activity. Drug Metabolism and Disposition, 2016, 44, 1867-1871.	1.7	9
61	Evidences of Biological Functions of Biliverdin Reductase A in the Bovine Epididymis. Journal of Cellular Physiology, 2016, 231, 1077-1089.	2.0	13
62	Phase II Drug-Metabolizing Polymorphisms and Smoking Predict Recurrence of Nonâ€“Muscle-Invasive Bladder Cancer: A Geneâ€“Smoking Interaction. Cancer Prevention Research, 2016, 9, 189-195.	0.7	11
63	Assay reproducibility of serum androgen measurements using liquid chromatographyâ€“tandem mass spectrometry. Journal of Steroid Biochemistry and Molecular Biology, 2016, 155, 56-62.	1.2	19
64	Epigenetic regulation of steroid inactivating UDP-glucuronosyltransferases by microRNAs in prostate cancer. Journal of Steroid Biochemistry and Molecular Biology, 2016, 155, 85-93.	1.2	32
65	The UGT2B28 Sex-steroid Inactivation Pathway Is a Regulator of Steroidogenesis and Modifies the Risk of Prostate Cancer Progression. European Urology, 2016, 69, 601-609.	0.9	36
66	Unravelling the transcriptomic landscape of the major phase II UDP-glucuronosyltransferase drug metabolizing pathway using targeted RNA sequencing. Pharmacogenomics Journal, 2016, 16, 60-70.	0.9	31
67	Cyclosporine and methotrexate-related pharmacogenomic predictors of acute graft-versus-host disease. Haematologica, 2015, 100, 275-283.	1.7	8
68	ABCC5 and ABCG1 polymorphisms predict irinotecan-induced severe toxicity in metastatic colorectal cancer patients. Pharmacogenetics and Genomics, 2015, 25, 573-583.	0.7	37
69	The UGT1 locus is a determinant of prostate cancer recurrence after prostatectomy. Endocrine-Related Cancer, 2015, 22, 77-85.	1.6	9
70	Quantitative Profiling of Human Renal UDP-glucuronosyltransferases and Glucuronidation Activity: A Comparison of Normal and Tumoral Kidney Tissues. Drug Metabolism and Disposition, 2015, 43, 611-619.	1.7	79
71	A novel UGT1 marker associated with better tolerance against irinotecan-induced severe neutropenia in metastatic colorectal cancer patients. Pharmacogenomics Journal, 2015, 15, 513-520.	0.9	19
72	Association Between Circulating Levels of Sex Steroid Hormones and Barrettâ€™s Esophagus in Men: A Caseâ€“Control Analysis. Clinical Gastroenterology and Hepatology, 2015, 13, 673-682.	2.4	30

#	Article	IF	Citations
73	Prediagnostic Sex Steroid Hormones in Relation to Male Breast Cancer Risk. Journal of Clinical Oncology, 2015, 33, 2041-2050.	0.8	65
74	A chromatography/tandem mass spectrometry method for the simultaneous profiling of ten endogenous steroids, including progesterone, adrenal precursors, androgens and estrogens, using low serum volume. Steroids, 2015, 104, 16-24.	0.8	51
75	Multiplexed Targeted Quantitative Proteomics Predicts Hepatic Glucuronidation Potential. Drug Metabolism and Disposition, 2015, 43, 1331-1335.	1.7	39
76	BCAT1 expression associates with ovarian cancer progression: possible implications in altered disease metabolism. Oncotarget, 2015, 6, 31522-31543.	0.8	84
77	Abstract 3448: Overexpression of the steroid inactivating UGT2B28 enzyme is associated with high circulating androgens, tumor aggressiveness and adverse prostate cancer outcome. , 2015, , .		0
78	Steroidogenic Germline Polymorphism Predictors of Prostate Cancer Progression in the Estradiol Pathway. Clinical Cancer Research, 2014, 20, 2971-2983.	3.2	27
79	Pharmacogenomics of Human Uridine Diphospho-Glucuronosyltransferases and Clinical Implications. Clinical Pharmacology and Therapeutics, 2014, 96, 324-339.	2.3	135
80	Importance of 5Î±-Reductase Gene Polymorphisms on Circulating and Intraprostatic Androgens in Prostate Cancer. Clinical Cancer Research, 2014, 20, 576-584.	3.2	27
81	Dual Roles for Splice Variants of the Glucuronidation Pathway as Regulators of Cellular Metabolism. Molecular Pharmacology, 2014, 85, 29-36.	1.0	22
82	Genetic variants in microRNAs and microRNA target sites predict biochemical recurrence after radical prostatectomy in localized prostate cancer. International Journal of Cancer, 2014, 135, 2661-2667.	2.3	40
83	Abstract 2207: An analysis of circulating sex steroid hormones in relation to Barrett's esophagus. , 2014, , .		0
84	Three-dimensional culture and cAMP signaling promote the maturation of human pluripotent stem cell-derived hepatocytes. Development (Cambridge), 2013, 140, 3285-3296.	1.2	138
85	Evidence for regulation of UDP-glucuronosyltransferase (UGT) 1A1 protein expression and activity via DNA methylation in healthy human livers. Journal of Pharmacy and Pharmacology, 2013, 65, 874-883.	1.2	28
86	Proteinâ€“protein interactions between the bilirubin-conjugating UDPglucuronosyltransferase UGT1A1 and its shorter isoform 2 regulatory partner derived from alternative splicing. Biochemical Journal, 2013, 450, 107-114.	1.7	6
87	Molecular Markers in Key Steroidogenic Pathways, Circulating Steroid Levels, and Prostate Cancer Progression. Clinical Cancer Research, 2013, 19, 699-709.	3.2	54
88	Testosterone challenge and androgen receptor activity in relation to <scp>UGT</scp>2B17 genotypes. European Journal of Clinical Investigation, 2013, 43, 248-255.	1.7	16
89	Modulation of the UGT2B7 Enzyme Activity by C-Terminally Truncated Proteins Derived from Alternative Splicing. Drug Metabolism and Disposition, 2013, 41, 2197-2205.	1.7	20
90	Expression of UGT2B7 is driven by two mutually exclusive promoters and alternative splicing in human tissues. Pharmacogenetics and Genomics, 2013, 23, 684-696.	0.7	10

#	Article	IF	Citations
91	The UDP-Glucuronosyltransferase (UGT) 1A Polymorphism c.2042C>G (rs8330) Is Associated with Increased Human Liver Acetaminophen Glucuronidation, Increased UGT1A Exon 5a/5b Splice Variant mRNA Ratio, and Decreased Risk of Unintentional Acetaminophen-Induced Acute Liver Failure. Journal of Pharmacology and Experimental Therapeutics, 2013, 345, 297-307.	1.3	75
92	The Relative Protein Abundance of UGT1A Alternative Splice Variants as a Key Determinant of Glucuronidation Activity In Vitro. Drug Metabolism and Disposition, 2013, 41, 694-697.	1.7	3
93	Refining theUGT1AHaplotype Associated with Irinotecan-Induced Hematological Toxicity in Metastatic Colorectal Cancer Patients Treated with 5-Fluorouracil/Irinotecan-Based Regimens. Journal of Pharmacology and Experimental Therapeutics, 2013, 345, 95-101.	1.3	58
94	Overexpression of uridine diphospho glucuronosyltransferase 2B17 in high-risk chronic lymphocytic leukemia. Blood, 2013, 121, 1175-1183.	0.6	48
95	Evidence for epigenetic regulation of UGT1A1 protein expression and activity in healthy human livers. FASEB Journal, 2013, 27, 270.5.	0.2	0
96	Worldwide variation in human drug-metabolism enzyme genes CYP2B6 and UGT2B7: implications for HIV/AIDS treatment. Pharmacogenomics, 2012, 13, 555-570.	0.6	59
97	Liquid Chromatographyâ€“Coupled Tandem Mass Spectrometry Based Assay to Evaluate Inosine-5â€²-monophosphate Dehydrogenase Activity in Peripheral Blood Mononuclear Cells from Stem Cell Transplant Recipients. Analytical Chemistry, 2012, 84, 216-223.	3.2	23
98	A liquid chromatographyâ€“tandem mass spectrometry (LCâ€“MS/MS) method for monitoring drug exposure in hematopoietic stem cell transplant recipients. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2012, 885-886, 131-137.	1.2	12
99	The Impact of Germline Genetic Variations in Hydroxysteroid (17-Beta) Dehydrogenases on Prostate Cancer Outcomes After Prostatectomy. European Urology, 2012, 62, 88-96.	0.9	33
100	Abstract 5534: Building the organization framework for biopsy-driven translational research: The Quebec Clinical Research Organization in Cancer (Q-CROC) experience. , 2012, , .		0
101	Deletions of the Androgen-MetabolizingUGT2BGenes Have an Effect on Circulating Steroid Levels and Biochemical Recurrence after Radical Prostatectomy in Localized Prostate Cancer. Journal of Clinical Endocrinology and Metabolism, 2011, 96, E1550-E1557.	1.8	54
102	2288 PROGNOSTIC IMPACT OF INHERITED GENETIC VARIATIONS IN SRD5A AND ANDROGEN INACTIVATING UGT2B GENES IN PROSTATE CANCER AFTER PROSTATECTOMY. Journal of Urology, 2011, 185, .	0.2	0
103	Bioavailability of testosterone enanthate dependent on genetic variation in the phosphodiesterase 7B but not on the uridine 5â€²-diphospho-glucuronosyltransferase (UGT2B17) gene.. Pharmacogenetics and Genomics, 2011, 21, 325-332.	0.7	24
104	Transcriptional diversity at the UGT2B7 locus is dictated by extensive pre-mRNA splicing mechanisms that give rise to multiple mRNA splice variants. Pharmacogenetics and Genomics, 2011, 21, 631-641.	0.7	26
105	SRD5A Polymorphisms and Biochemical Failure After Radical Prostatectomy. European Urology, 2011, 60, 1226-1234.	0.9	41
106	Immunohistochemical expression of conjugating UGT1Aâ€derived isoforms in normal and tumoral drugâ€metabolizing tissues in humans. Journal of Pathology, 2011, 223, 425-435.	2.1	27
107	Correlation between circulatory, local prostatic, and intraâ€prostatic androgen levels. Prostate, 2011, 71, 909-914.	1.2	28
108	Profiling of Endogenous Estrogens, Their Precursors, and Metabolites in Endometrial Cancer Patients: Association with Risk and Relationship to Clinical Characteristics. Journal of Clinical Endocrinology and Metabolism, 2011, 96, E330-E339.	1.8	76

#	Article	IF	Citations
109	In Vitro Investigation of Human UDP-Glucuronosyltransferase Isoforms Responsible for Tacrolimus Glucuronidation: Predominant Contribution of UGT1A4. Drug Metabolism and Disposition, 2011, 39, 1127-1130.	1.7	26
110	Chemokine (C-C Motif) Receptor 5 â^'2459 Genotype in Patients Receiving Highly Active Antiretroviral Therapy: Race-Specific Influence on Virologic Success. Journal of Infectious Diseases, 2011, 204, 291-298.	1.9	10
111	Extensive splicing of transcripts encoding the bile acid-conjugating enzyme UGT2B4 modulates glucuronidation. Pharmacogenetics and Genomics, 2010, 20, 195-210.	0.7	21
112	Pharmacogenetic Impact of UDP-Glucuronosyltransferase Metabolic Pathway and Multidrug Resistanceâ€"Associated Protein 2 Transport Pathway on Mycophenolic Acid in Thoracic Transplant Recipients: An Exploratory Study. Pharmacotherapy, 2010, 30, 1097-1108.	1.2	21
113	Regulation of UGT1A1 and HNF1 transcription factor gene expression by DNA methylation in colon cancer cells. BMC Molecular Biology, 2010, 11, 9.	3.0	67
114	Modulation of the Human Glucuronosyltransferase UGT1A Pathway by Splice Isoform Polypeptides Is Mediated through Protein-Protein Interactions. Journal of Biological Chemistry, 2010, 285, 3600-3607.	1.6	38
115	Alternatively Spliced Products of theUGT1AGene Interact with the Enzymatically Active Proteins to Inhibit Glucuronosyltransferase Activity In Vitro. Drug Metabolism and Disposition, 2010, 38, 1785-1789.	1.7	24
116	The Human UGT1A3 Enzyme Conjugates Norursodeoxycholic Acid into a C23-ester Glucuronide in the Liver. Journal of Biological Chemistry, 2010, 285, 1113-1121.	1.6	19
117	Alternative-splicing forms of the major phase II conjugating UGT1A gene negatively regulate glucuronidation in human carcinoma cell lines. Pharmacogenomics Journal, 2010, 10, 431-441.	0.9	27
118	Circulating Estrogens in Endometrial Cancer Cases and Their Relationship with Tissular Expression of Key Estrogen Biosynthesis and Metabolic Pathways. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 2689-2698.	1.8	70
119	2122 COPY NUMBER VARIATION OF SEX-STEROID METABOLIZING GENES AS BIOMARKERS OF PROSTATE CANCER RECURRENCE AFTER PROSTATECTOMY: LOOKING AT THE END OF THE ANDROGENIC SIGNAL. Journal of Urology, 2010, 183, .	0.2	0
120	UGT genomic diversity: beyond gene duplication. Drug Metabolism Reviews, 2010, 42, 24-44.	1.5	124
121	Abstract LB-204: Gene expression profiling of hormone-regulating pathways in tumoral and peritumoral breast tissues. , 2010, , .		0
122	Deferiprone Glucuronidation by Human Tissues and Recombinant UDP Glucuronosyltransferase 1A6: An in Vitro Investigation of Genetic and Splice Variants. Drug Metabolism and Disposition, 2009, 37, 322-329.	1.7	40
123	In Vitro Glucuronidation of Fenofibric Acid by Human UDP-Glucuronosyltransferases and Liver Microsomes. Drug Metabolism and Disposition, 2009, 37, 2236-2243.	1.7	17
124	Glucuronidation of the Antiretroviral Drug Efavirenz by UGT2B7 and an in Vitro Investigation of Drug-Drug Interaction with Zidovudine. Drug Metabolism and Disposition, 2009, 37, 1793-1796.	1.7	134
125	Analysis of inherited genetic variations at theUGT1locus in the French-Canadian population. Human Mutation, 2009, 30, 677-687.	1.1	28
126	Copy-number variations (CNVs) of the human sex steroid metabolizing genesUGT2B17andUGT2B28and their associations with aUGT2B15functional polymorphism. Human Mutation, 2009, 30, 1310-1319.	1.1	49

#	Article	IF	Citations
127	Profiling Endogenous Serum Estrogen and Estrogen-Glucuronides by Liquid Chromatographyâ^'Tandem Mass Spectrometry. Analytical Chemistry, 2009, 81, 10143-10148.	3.2	28
128	Genetic variations in UGT1A1 and UGT2B7 and endometrial cancer risk. Pharmacogenetics and Genomics, 2009, 19, 239-243.	0.7	21
129	A pharmacogenetics study of the human glucuronosyltransferase UGT1A4. Pharmacogenetics and Genomics, 2009, 19, 945-954.	0.7	45
130	UGT1A1 and UGT1A9 functional variants, meat intake, and colon cancer, among Caucasians and African-Americans. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2008, 644, 56-63.	0.4	48
131	Influence of UDP-Glucuronosyltransferase Polymorphisms on Mycophenolate Mofetil-Induced Side Effects in Kidney Transplant Patients. Transplantation Proceedings, 2008, 40, 708-710.	0.3	15
132	Pharmacokinetics of mycophenolate mofetil and its glucuronide metabolites in healthy volunteers. Pharmacogenomics, 2008, 9, 869-879.	0.6	40
133	Downregulation of Hepatic Acetylation of Drugs in Chronic Renal Failure. Journal of the American Society of Nephrology: JASN, 2008, 19, 1352-1359.	3.0	38
134	A pharmacogenomics study of the human estrogen glucuronosyltransferase UGT1A3. Pharmacogenetics and Genomics, 2007, 17, 481-495.	0.7	33
135	Genetic diversity at the UGT1 locus is amplified by a novel 3â€² alternative splicing mechanism leading to nine additional UGT1A proteins that act as regulators of glucuronidation activity. Pharmacogenetics and Genomics, 2007, 17, 1077-1089.	0.7	81
136	Regulation of the UGT1A1 bilirubin-conjugating pathway: Role of a new splicing event at the UGT1A locus. Hepatology, 2007, 45, 128-138.	3.6	90
137	Sensitive high-performance liquid chromatographyâ€“tandem mass spectrometry method for quantitative analysis of mycophenolic acid and its glucuronide metabolites in human plasma and urine. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2007, 858, 159-167.	1.2	30
138	The Impact of UGT1A8, UGT1A9, and UGT2B7 Genetic Polymorphisms on the Pharmacokinetic Profile of Mycophenolic Acid After a Single Oral Dose in Healthy Volunteers. Clinical Pharmacology and Therapeutics, 2007, 81, 392-400.	2.3	146
139	Irinotecan Inactivation Is Modulated by Epigenetic Silencing of UGT1A1 in Colon Cancer. Clinical Cancer Research, 2006, 12, 1850-1858.	3.2	82
140	THE NOVEL UGT1A9 INTRONIC I399 POLYMORPHISM APPEARS AS A PREDICTOR OF 7-ETHYL-10-HYDROXYCAMPTOTHECIN GLUCURONIDATION LEVELS IN THE LIVER. Drug Metabolism and Disposition, 2006, 34, 1220-1228.	1.7	71
141	Influence of Nonsynonymous Polymorphisms of UGT1A8 and UGT2B7 Metabolizing Enzymes on the Formation of Phenolic and Acyl Glucuronides of Mycophenolic Acid. Drug Metabolism and Disposition, 2006, 34, 1539-1545.	1.7	91
142	Characterization of Common UGT1A8, UGT1A9, and UGT2B7 Variants with Different Capacities to Inactivate Mutagenic 4-Hydroxylated Metabolites of Estradiol and Estrone. Cancer Research, 2006, 66, 125-133.	0.4	100
143	UGT1A8 and UGT1A9 as Molecular Determinants of Mycophenolate Mofetil (MMF) Pharmacokinetics.. Blood, 2006, 108, 3191-3191.	0.6	0
144	UGT1A1 polymorphisms are important determinants of dietary carcinogen detoxification in the liver. Hepatology, 2005, 42, 448-457.	3.6	70

#	Article	IF	Citations
145	Reply:. Hepatology, 2005, 42, 1463-1463.	3.6	0
146	Hepatic Expression of the UGT1A9 Gene Is Governed by Hepatocyte Nuclear Factor 4Î±. Molecular Pharmacology, 2005, 67, 241-249.	1.0	61
147	Joint Effects between UDP-Glucuronosyltransferase 1A7 Genotype and Dietary Carcinogen Exposure on Risk of Colon Cancer. Cancer Epidemiology Biomarkers and Prevention, 2005, 14, 1626-1632.	1.1	62
148	In Utero and Lactational Exposure to an Environmentally Relevant Organochlorine Mixture Disrupts Reproductive Development and Function in Male Rats1. Biology of Reproduction, 2005, 73, 414-426.	1.2	26
149	Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily. Pharmacogenetics and Genomics, 2005, 15, 677-685.	0.7	708
150	Reduced Fertility in Male Mice Deficient in the Zinc Metallopeptidase NL1. Molecular and Cellular Biology, 2004, 24, 4428-4437.	1.1	37
151	The Functional UGT1A1 Promoter Polymorphism Decreases Endometrial Cancer Risk. Cancer Research, 2004, 64, 1202-1207.	0.4	84
152	GLUCURONIDATION AND THE UDP-GLUCURONOSYLTRANSFERASES IN HEALTH AND DISEASE. Drug Metabolism and Disposition, 2004, 32, 281-290.	1.7	224
153	Specificity and Regioselectivity of the Conjugation of Estradiol, Estrone, and Their Catecholestrogen and Methoxyestrogen Metabolites by Human Uridine Diphospho-glucuronosyltransferases Expressed in Endometrium. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 5222-5232.	1.8	175
154	A novel functional polymorphism in the uridine diphosphateâ€“glucuronosyltransferase 2B7 promoter with significant impact on promoter activity. Clinical Pharmacology and Therapeutics, 2004, 75, 223-233.	2.3	139
155	THE MAIN ROLE OF UGT1A9 IN THE HEPATIC METABOLISM OF MYCOPHENOLIC ACID AND THE EFFECTS OF NATURALLY OCCURRING VARIANTS. Drug Metabolism and Disposition, 2004, 32, 775-778.	1.7	192
156	Metabolic inactivation of estrogens in breast tissue by UDP-glucuronosyltransferase enzymes: an overview. Breast Cancer Research, 2004, 6, 246-54.	2.2	102
157	Boar sperm storage capacity of BTS and Androhep Plus: viability, motility, capacitation, and tyrosine phosphorylation. Theriogenology, 2004, 62, 874-886.	0.9	56
158	Identification of common polymorphisms in the promoter of the UGT1A9 gene. Pharmacogenetics and Genomics, 2004, 14, 501-515.	5.7	191
159	Polymorphisms in Steroid Hormone Pathway Genes and Mammographic Density. Breast Cancer Research and Treatment, 2003, 77, 27-36.	1.1	78
160	Pharmacogenomics of human UDP-glucuronosyltransferase enzymes. Pharmacogenomics Journal, 2003, 3, 136-158.	0.9	386
161	Novel Functional Polymorphisms in the UGT1A7 and UGT1A9 Glucuronidating Enzymes in Caucasian and African-American Subjects and Their Impact on the Metabolism of 7-Ethyl-10-hydroxycamptothecin and Flavopiridol Anticancer Drugs. Journal of Pharmacology and Experimental Therapeutics, 2003, 307, 117-128.	1.3	185
162	The UDP-glucuronosyltransferase 1A9 Enzyme Is a Peroxisome Proliferator-activated Receptor Î± and Î³ Target Gene. Journal of Biological Chemistry, 2003, 278, 13975-13983.	1.6	113

#	Article	IF	Citations
163	Stereoselective Conjugation of Oxazepam by Human UDP-Glucuronosyltransferases (UGTs): S-Oxazepam Is Glucuronidated by UGT2B15, While R-Oxazepam Is Glucuronidated by UGT2B7 and UGT1A9. Drug Metabolism and Disposition, 2002, 30, 1257-1265.	1.7	155
164	An Environmentally Relevant Organochlorine Mixture Impairs Sperm Function and Embryo Development in the Porcine Model1. Biology of Reproduction, 2002, 67, 80-87.	1.2	43
165	Common Human UGT1A Polymorphisms and the Altered Metabolism of Irinotecan Active Metabolite 7-Ethyl-10-hydroxycamptothecin (SN-38). Molecular Pharmacology, 2002, 62, 608-617.	1.0	338
166	In vitro characterization of hepatic flavopiridol metabolism using human liver microsomes and recombinant UGT enzymes. Pharmaceutical Research, 2002, 19, 588-594.	1.7	43
167	Characterization of benzo(a)pyrene-trans-7,8-dihydrodiol glucuronidation by human tissue microsomes and overexpressed UDP-glucuronosyltransferase enzymes. Cancer Research, 2002, 62, 1978-86.	0.4	74
168	Tobacco Carcinogen-Detoxifying Enzyme UGT1A7 and Its Association With Orolaryngeal Cancer Risk. Journal of the National Cancer Institute, 2001, 93, 1411-1418.	3.0	136
169	Structural heterogeneity at the UDP-glucuronosyltransferase 1 locus: functional consequences of three novel missense mutations in the human UGT1A7 gene. Pharmacogenetics and Genomics, 2000, 10, 629-644.	5.7	168
170	Direct haplotyping of kilobase-size DNA using carbon nanotube probes. Nature Biotechnology, 2000, 18, 760-763.	9.4	164
171	Title is missing!. Nature Biotechnology, 2000, 18, 760-763.	9.4	30
172	Characterization of UDP-glucuronosyltransferases active on steroid hormones. Journal of Steroid Biochemistry and Molecular Biology, 1999, 69, 413-423.	1.2	101
173	Effect of fibroblastic growth factors (FGF) on steroid UDP-glucuronosyltransferase expression and activity in the LNCaP cell line. Journal of Steroid Biochemistry and Molecular Biology, 1998, 64, 43-48.	1.2	17
174	Characterization and regulation of UDP-glucuronosyltransferases in steroid target tissues. Journal of Steroid Biochemistry and Molecular Biology, 1998, 65, 301-310.	1.2	107
175	Effect of Interleukins on UGT2B15 and UGT2B17 Steroid Uridine Diphosphate-Glucuronosyltransferase Expression and Activity in the LNCaP Cell Line¹. Endocrinology, 1998, 139, 2375-2381.	1.4	49
176	Differential Regulation of Two Uridine Diphospho-Glucuronosyltransferases, UGT2B15 and UGT2B17, in Human Prostate LNCaP Cells1. Endocrinology, 1997, 138, 2998-3005.	1.4	91
177	Evidence for a role of glucuronosyltransferase in the regulation of androgen action in the human prostatic cancer cell line LNCaP. Journal of Steroid Biochemistry and Molecular Biology, 1996, 57, 225-231.	1.2	21
178	Expression of transcripts encoding steroid UDP-glucuronosyltransferases in human prostate hyperplastic tissue and the LNCaP cell line. Molecular and Cellular Endocrinology, 1995, 113, 165-173.	1.6	38
179	Glucuronosyltransferase activity in human cancer cell line LNCaP. Molecular and Cellular Endocrinology, 1995, 107, 131-139.	1.6	27
180	Specificity of glucuronosyltransferase activity in the human cancer cell line LNCaP, evidence for the presence of at least two glucuronosyltransferase enzymes. Journal of Steroid Biochemistry and Molecular Biology, 1995, 55, 355-362.	1.2	24

#	Article	IF	Citations
181	Differential Regulation of Two Uridine Diphospho-Glucuronosyltransferases, UGT2B15 and UGT2B17, in Human Prostate LNCaP Cells. , 0, .		32
182	Effect of Interleukins on UGT2B15 and UGT2B17 Steroid Uridine Diphosphate-Glucuronosyltransferase Expression and Activity in the LNCaP Cell Line. , 0, .		22